Pyridoxine: Nursing Drug Guide, INH Neuropathy Prevention & NCLEX Review
Vitamin B6 prevents isoniazid-induced deficiency neuropathy—but duplicate OTC supplements, prescribed prophylaxis, and high-dose therapy can cause sensory neuropathy from excess B6. Pyridoxine also antagonizes levodopa unless carbidopa is present. Reconcile every B6 source on the MAR, give INH prophylaxis per labeling, and monitor for new numbness, tingling, or somnolence.
Missed or under-dosed pyridoxine during isoniazid therapy allows preventable peripheral neuropathy. The opposite error—stacking prescribed INH prophylaxis with OTC vitamin B6 or high-dose supplements—can cause paresthesia and, at chronic high intake, severe sensory neuropathy per NIH ODS. Labeling warns that pyridoxine antagonizes levodopa when daily supplement pyridoxine exceeds 5 mg unless the patient takes carbidopa-levodopa. For INH ingestion above 10 g, labeling directs gram-for-gram pyridoxine antidote dosing (4 g IV then 1 g IM every 30 minutes).
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: complete medication reconciliation for all vitamin B6 sources (prescribed, multivitamin, OTC). On INH therapy, confirm 100 mg daily for 3 weeks then 30 mg maintenance unless orders differ. Hold or clarify supplements above 5 mg/day pyridoxine in patients on levodopa monotherapy. Teach patients to report new numbness, tingling, burning feet, or somnolence—both deficiency and excess B6 can present with neuropathy cues.
Most common brand names
Pyridoxine (vitamin B6) is available as oral tablets and capsules, combination B-complex products, and as Pyridoxine Hydrochloride Injection, USP (100 mg/mL) for intramuscular or intravenous use when oral therapy is not feasible.
Common presentations: 100 mg/mL multiple-dose vials (Fresenius Kabi); oral pyridoxine 25–100 mg tablets; multivitamins containing 2–10 mg B6. Do not confuse with: cyanocobalamin (B12), thiamine (B1), or folic acid—different vitamins with distinct neuropathy and interaction profiles.
Why we give it — Indications
Pyridoxine treats and prevents vitamin B6 deficiency. Nurses most often administer it with isoniazid for tuberculosis prophylaxis or treatment to prevent INH-induced peripheral neuropathy. Parenteral therapy is indicated when oral intake is impaired by nausea, vomiting, or malabsorption.
| Use | Detail |
|---|---|
| INH-induced deficiency | Drug-induced deficiency from isoniazid—labeling recommends prophylactic pyridoxine to prevent peripheral neuropathy during anti-tuberculosis therapy. |
| Inadequate dietary intake | Corrects deficiency from poor diet; follow-up with oral multivitamin containing 2–5 mg pyridoxine after parenteral course per labeling. |
| Vitamin B6 dependency syndromes | Inborn errors such as B6-dependent convulsions or B6-responsive anemia may require high therapeutic doses (up to 600 mg/day) and lifelong maintenance (30 mg/day) per labeling. |
| INH poisoning antidote | When more than 10 g isoniazid is ingested, labeling directs gram-for-gram pyridoxine replacement—emergency IV/IM protocol. |
| Pregnancy nausea (adjunct) | Labeling notes pyridoxine is sometimes of value in nausea and vomiting of pregnancy; requirements increase during pregnancy (Pregnancy Category A). |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Natural vitamin B6 forms (pyridoxine, pyridoxal, pyridoxamine) convert to pyridoxal phosphate—the physiologically active coenzyme in protein, carbohydrate, and fat metabolism. Pyridoxal phosphate participates in amino acid decarboxylation, transamination, and conversion of tryptophan to niacin or serotonin. Isoniazid interferes with pyridoxine metabolism and increases requirements; without replacement, peripheral neuropathy develops. At pharmacologic doses, pyridoxine increases peripheral metabolism of levodopa to dopamine peripherally, reducing levodopa central availability—hence the labeling restriction in levodopa monotherapy.
Dosing overview
Each mL of Pyridoxine Hydrochloride Injection, USP contains 100 mg pyridoxine hydrochloride. Oral products vary—always verify total daily pyridoxine from all sources (prescribed, multivitamin, OTC). Institutional TB protocols may differ; align with prescriber orders and current labeling.
Missed dose: For INH prophylaxis, give the missed dose when remembered the same day if policy allows; do not double doses. Contact pharmacy for maintenance-phase gaps because missed prophylaxis during INH therapy increases neuropathy risk. For dependency syndromes on lifelong 30 mg daily, missed doses may precipitate seizures—escalate per prescriber plan.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Half-life | 15–20 days (labeling) | Body pool is small (16–25 mg total); prolonged high intake can accumulate neurologic risk before symptoms are recognized |
| Metabolism / elimination | Degraded to 4-pyridoxic acid in liver; excreted in urine | Renal impairment may affect elimination of metabolites; monitor neuropathy cues with prolonged parenteral use |
| Adult minimum requirement | About 1.25 mg/day; RDA up to ~2.2 mg (labeling) | INH, oral contraceptives, and pregnancy increase needs—prophylactic 100 mg is pharmacologic, not nutritional |
| Protein linkage | Requirement rises with dietary protein | Malnourished TB patients may have compounded deficiency risk beyond INH alone |
| Well-tolerated acute dose (human) | 25 mg/kg tolerated (overdosage section) | Do not confuse tolerated single exposure with safe chronic megadose supplementation |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Reconcile all pyridoxine sources—prescribed INH prophylaxis, multivitamins, protein supplements, and OTC B6—to prevent duplicate high-dose therapy
- Confirm indication (INH prophylaxis, deficiency, dependency, or antidote pathway) and whether route is PO, IM, or IV
- Review neurologic baseline: numbness, tingling, burning sensation in feet or hands, gait, and whether patient takes levodopa or anticonvulsants
Contraindications
- History of sensitivity to pyridoxine or to any ingredient in Pyridoxine Hydrochloride Injection, USP (including chlorobutanol)
- Not specified beyond hypersensitivity in the reviewed prescribing information
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Levodopa (without carbidopa) | Pyridoxine antagonizes levodopa; supplements >5 mg pyridoxine daily should be avoided per labeling | Reconcile vitamins; carbidopa-levodopa combination may be used concurrently per labeling |
| Isoniazid | INH induces functional B6 deficiency—prophylactic pyridoxine prevents neuropathy; antidote dosing for massive ingestion | Ensure prophylaxis on MAR; do not stop B6 while INH continues unless prescriber directs |
| Phenytoin / carbamazepine | NIH ODS notes anticonvulsants may increase B6 breakdown and lower plasma B6; labeling lists B6-dependent convulsions as an indication | Monitor for deficiency neuropathy and therapeutic levels; coordinate with neurology and pharmacy |
| Folic acid status | Labeling reports low serum folic acid levels with pyridoxine therapy | Trend folate when clinically indicated; do not assume neuropathy is always B6-related |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: Tablets, capsules, or multivitamin formulations per order—often used for INH maintenance (30 mg daily) after initial higher-dose phase.
IM / IV (injection): Pyridoxine Hydrochloride Injection, USP 100 mg/mL may be given intramuscularly or intravenously per labeling when oral route is not feasible. Inspect for particulate matter and discoloration before every dose; protect from light; use only if solution is clear and seal intact.
- For IM: standard intramuscular injection technique; rotate sites with repeated dosing
- For IV: administer per institutional policy and prescriber order—often slow IV push or diluted infusion for high-dose antidote protocols
- Document total milligrams of pyridoxine given, especially during INH poisoning treatment when gram doses are required
Labeling warns that aluminum in parenteral products may reach toxic levels with prolonged administration when kidney function is impaired; premature neonates are particularly at risk. Monitor renal function and cumulative parenteral exposure per facility policy.
Preparation and compatibility
| Topic | Guidance |
|---|---|
| Product concentration | 100 mg pyridoxine hydrochloride per mL; 1 mL fill in 2 mL multiple-dose vial per labeling |
| Excipients | Contains 0.5% chlorobutanol anhydrous (chloral derivative); pH adjusted with sodium hydroxide (2.0–3.8) |
| Visual inspection | Inspect for particulate matter and discoloration prior to administration whenever solution and container permit |
| Light protection | PROTECT FROM LIGHT—pyridoxine is slowly affected by sunlight per labeling description |
| Storage | Store at 20° to 25°C (68° to 77°F); controlled room temperature per USP |
| Compatibility | Verify IV compatibility with pharmacy for high-dose antidote infusions; no universal diluent guidance in the reviewed injection labeling—follow institutional references |
On a small screen, swipe or scroll sideways to see the full table.
Expected therapeutic response
- Prevention of new INH-related peripheral neuropathy when prophylaxis starts with anti-tuberculosis therapy
- Stabilization or improvement of existing mild deficiency symptoms (glossitis, irritability, seborrheic dermatitis per NIH ODS) over weeks
- Resolution of burning or tingling when due to B6 deficiency—not progression of symptoms from excess B6
- In B6-dependent convulsions, reduced seizure frequency when therapeutic doses are maintained per specialist plan
- Absence of new somnolence or progressive distal numbness suggesting toxicity from duplicate supplementation
Adverse effects
| Adverse effect | Notes | Nursing response |
|---|---|---|
| Paresthesia | Listed in labeling; also a toxicity signal at chronic high doses per NIH ODS | Distinguish INH neuropathy from B6 excess—review total daily dose and trend symptoms |
| Somnolence | Reported adverse reaction per labeling | Assess sedation, falls risk, and concomitant CNS medications; notify prescriber if new or worsening |
| Low serum folic acid | Reported with pyridoxine therapy per labeling | Monitor folate when clinically indicated; coordinate supplementation per prescriber |
| Dependence (200 mg/day) | Labeling notes dependence symptoms in adults given 200 mg daily followed by withdrawal | Do not stop high-dose therapy abruptly without prescriber taper plan |
| Sensory neuropathy (high chronic dose) | NIH ODS: chronic oral intake of 1–6 g/day for 12–40 months linked to severe progressive sensory neuropathy; ataxia reported | Reconcile OTC and prescribed sources; reduce dose per prescriber/pharmacist |
| Levodopa antagonism | Not an allergy—pharmacologic reduction of levodopa effect when B6 >5 mg/day without carbidopa | Hold non-prescribed B6; notify neurology/prescriber if Parkinson symptoms worsen |
On a small screen, swipe or scroll sideways to see the full table.
Red flags — Stop and act
Escalate when neuropathy cues worsen despite prophylaxis, when toxicity from duplicate B6 is suspected, or during INH poisoning antidote therapy.
- Progressive distal numbness, burning, or gait instability on INH—may signal inadequate prophylaxis OR excess B6; hold further unsupervised OTC supplements and notify prescriber
- New somnolence, ataxia, or loss of proprioception with total B6 intake far above nutritional needs—suspected B6 toxicity per NIH ODS
- Worsening Parkinson symptoms in a patient on levodopa monotherapy who started high-dose vitamin B6—antagonism per labeling
- Seizures in B6-dependent patients when maintenance doses are missed—urgent prescriber contact
- Known or suspected ingestion of >10 g isoniazid—initiate gram-for-gram pyridoxine antidote pathway and emergency escalation per facility protocol
- New confusion with high-dose parenteral antidote administration—assess neurologic status and coordinate with toxicology services
Overdose, toxicity, and antidote
Labeling states a dose of 25 mg/kg is well tolerated in humans. In animals, 3 to 4 g/kg produces convulsions and death. NIH ODS reports that chronic oral intake of 1–6 g per day for 12–40 months causes severe progressive sensory neuropathy in adults.
INH poisoning antidote
For poisoning caused by ingestion of more than 10 g of isoniazid, labeling directs an equal amount of pyridoxine: 4 g intravenously followed by 1 g intramuscularly every 30 minutes. This is a medical emergency—activate institutional response, continuous monitoring, and toxicology consultation per facility protocol and local emergency guidance.
Management of B6 excess
Stop excess supplementation; most neuropathy from high B6 intake improves after discontinuation per NIH ODS, though recovery may be incomplete. Contact local poison control or medical toxicology services when supratherapeutic ingestion is suspected, per facility protocol.
Look-alike / sound-alike and error prevention
- Pyridoxine vs pyridoxamine vs pyridoxal—all are vitamin B6 forms; verify the ordered product and total B6 milligrams
- Vitamin B6 vs vitamin B12 (cyanocobalamin)—sound similar in conversation; TB patients may need both—confirm correct vial and dose
- 100 mg/mL injection vs 100 mg oral tablet—route and volume errors; independent double-check high-dose antidote math
- INH prophylaxis duplication—prescribed 100 mg plus patient-brought OTC 50 mg plus B-complex multivitamin stacks dose silently
- Levodopa interaction missed on reconciliation—OTC “stress B” supplements often contain 50–100 mg pyridoxine
High-risk populations
| Population | Considerations |
|---|---|
| Patients on isoniazid | Highest nursing touchpoint—100 mg daily × 3 weeks then 30 mg maintenance prevents neuropathy; missed prophylaxis is a preventable harm |
| Levodopa therapy (without carbidopa) | Avoid supplements >5 mg pyridoxine daily per labeling—motor symptom relapse risk |
| B6 dependency syndromes | May require up to 600 mg/day therapeutically and 30 mg daily for life—abrupt discontinuation risks seizures |
| Renal impairment / premature neonates | Aluminum from prolonged parenteral products may accumulate—labeling CNS and bone toxicity warning |
| Pregnancy | Pregnancy Category A; requirements increase during pregnancy. Labeling notes use for nausea and vomiting of pregnancy in some patients. |
| Lactation | Requirements increase during lactation; many drugs excreted in human milk—use caution when administering parenteral pyridoxine per labeling |
| Oral contraceptive users | Labeling notes increased pyridoxine requirements—assess total intake from supplements |
| Pediatrics | Safety and effectiveness of injection not established in children per labeling—follow specialist and institutional guidance |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Peripheral neurologic exam each visit during INH therapy—numbness, tingling, burning, reflexes, gait, and fine motor function
- Total daily pyridoxine dose from all sources at admission and each medication review
- Parkinson symptom control in patients on levodopa when any vitamin product is introduced or changed
- Folic acid level when clinically indicated—labeling reports low serum folic acid with pyridoxine
- Renal function with prolonged parenteral therapy because of aluminum content warning
Document
- Indication (INH prophylaxis, deficiency, dependency, antidote), dose in mg, route, and phase (100 mg induction vs 30 mg maintenance)
- Patient report of OTC supplements and teach-back on not adding extra B6 without prescriber approval
- Neurologic assessment trends and prescriber notification when symptoms progress despite prophylaxis
Patient teaching
- “This vitamin prevents nerve problems from your tuberculosis medicine—take it exactly as ordered for the full course of isoniazid.”
- Do not add extra vitamin B6, B-complex, or “stress” supplements unless your clinician approves—too much B6 can also hurt nerves
- Report numbness, tingling, burning in feet or hands, sleepiness, trouble walking, or worsening tremor/stiffness if you take Parkinson medicines
- After the first 3 weeks, you may switch to a lower maintenance dose—confirm the new dose at discharge and with pharmacy
- Store injection vials protected from light; oral tablets at room temperature per product labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to pyridoxine or injection ingredients
- Duplicate high-dose B6 from multiple products pushing total intake well above ordered prophylaxis without prescriber awareness
- Levodopa monotherapy and order/supplement would exceed 5 mg pyridoxine daily
- Particulate matter, discoloration, or broken seal on parenteral product
- Progressive neuropathy despite adherence—may need dose adjustment, INH review, or toxicity workup before continuing unsupervised supplementation
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| INH phase change | Week 4: verify transition from 100 mg to 30 mg maintenance is on the MAR—common transition error |
| Injection math | 100 mg/mL vial: 0.3 mL = 30 mg; 1 mL = 100 mg—label syringe in mg and mL |
| Light protection | Store and handle vials per PROTECT FROM LIGHT labeling |
| OTC reconciliation | Ask specifically about B-complex, energy drinks with B vitamins, and online supplement stacks |
| TB clinic workflow | Bundle B6 education with directly observed INH when policy supports co-administration |
On a small screen, swipe or scroll sideways to see the full table.
Clinical practice integration and workflow
Pyridoxine errors cluster around omitted INH prophylaxis, silent duplicate OTC dosing, and levodopa antagonism. Complete medication reconciliation at every TB visit, discharge, and care transition. Treat B6 as a high-stakes adjunct—not a harmless vitamin.
1. Check-before-you-give protocol
- Right patient, drug (pyridoxine), dose in mg, route, and indication (prophylaxis vs maintenance vs antidote)
- Sum all B6 sources—prescribed, multivitamin, protein powder, OTC
- Confirm concurrent isoniazid on MAR when prophylaxis is the indication
- Neurologic baseline documented; levodopa therapy flagged for interaction screen
2. High-alert and safety badge
Not a standard ISMP high-alert drug — INH neuropathy prevention and duplicate-dose toxicity require reconciliation vigilanceMany TB programs treat pyridoxine as mandatory with INH—document omissions as a patient-safety event per institutional policy.
3. Clinical workflow: hold and question rules
- If neuropathy progresses on 100 mg prophylaxis, notify prescriber—do not add OTC B6 without orders
- If patient on levodopa starts a multivitamin, calculate total pyridoxine before first dose
- If INH overdose suspected, initiate antidote protocol—do not wait for symptom-only management
4. Critical teach-back questions
- “Why are you taking vitamin B6 with your TB medicine?” (To prevent nerve damage from isoniazid—I take it for the whole time I am on INH.)
- “Can you buy extra B6 at the pharmacy to help faster?” (No—only what my clinician prescribed; extra can cause nerve problems.)
5. Care coordination
TB / infectious diseases prescriber: Confirm prophylaxis duration matches INH course and maintenance transition timing
Pharmacist: Reconcile total B6 dose, levodopa interaction screen, and antidote supply for emergency INH ingestion protocols
🧠 Quick mental checklist
- Is isoniazid on the MAR—and is pyridoxine paired with it?
- What is the total B6 mg from all sources today?
- Is this induction (100 mg) or maintenance (30 mg)?
- Does this patient take levodopa without carbidopa?
- Are feet/hands symptoms better, stable, or worse since last visit?
Pyridoxine NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for pyridoxine using a tabbed TB-clinic case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), neuropathy trend interpretation, INH antidote documentation cloze, levodopa interaction judgment, and matrix urgency—recognise INH prophylaxis and duplicate B6 cues → analyse levodopa antagonism → prioritise reconciliation → act → evaluate outcomes with neurologic symptom trends.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Isoniazid 300 mg PO daily — active TB treatment month 2
- Pyridoxine 100 mg PO daily — week 3 of induction prophylaxis
- Levodopa 100 mg PO TID — Parkinson disease (no carbidopa on MAR)
- Patient-reported OTC B-complex (50 mg pyridoxine) taken each morning— not on MAR
- Serum folate 2.8 ng/mL (low-normal) — prior value 4.1 ng/mL
- CBC within reference range
- Creatinine 0.9 mg/dL; eGFR >90 mL/min/1.73 m²
- No plasma pyridoxal phosphate level available
- 34-year-old receiving directly observed INH for pulmonary tuberculosis
- Parkinson disease diagnosed 2 years ago; tremor worse past 10 days
- Denies alcohol use; adequate protein intake per dietitian note
- Allergies: NKDA
- Patient doubled prescribed pyridoxine yesterday (“more prevents nerve problems”)
- Reports bilateral foot numbness and burning worse than last visit
- Gait steady; denies somnolence
- Pharmacy sticker on INH bottle: “take with vitamin B6 as ordered”
Answer key & rationale
Frequently asked questions
Why is pyridoxine given with isoniazid for tuberculosis treatment?
Isoniazid can cause drug-induced vitamin B6 deficiency and peripheral neuropathy. Fresenius Kabi Pyridoxine Hydrochloride Injection labeling recommends 100 mg daily for 3 weeks followed by 30 mg maintenance daily for INH-related deficiency. Nurses should confirm prophylactic B6 is on the MAR and reconcile OTC supplements to avoid duplicate high-dose therapy.
Can patients on levodopa take pyridoxine supplements?
Labeling states patients treated with levodopa should avoid supplemental vitamins containing more than 5 mg pyridoxine in the daily dose because pyridoxine antagonizes levodopa. Pyridoxine may be used concurrently when the patient receives a carbidopa-levodopa combination product.
What are signs of excessive pyridoxine (vitamin B6) intake?
Labeling reports paresthesia and somnolence as adverse reactions. NIH ODS notes that chronic oral intake of 1–6 g per day for 12–40 months can cause severe progressive sensory neuropathy. Dependence symptoms have been noted in adults given only 200 mg daily followed by withdrawal. Reconcile prescribed INH prophylaxis with multivitamins and OTC B6.
What is the antidote dosing for isoniazid poisoning?
For poisoning caused by ingestion of more than 10 g of isoniazid, labeling directs an equal amount of pyridoxine: 4 g intravenously followed by 1 g intramuscularly every 30 minutes. This is an emergency pathway—activate institutional response and involve prescriber, pharmacy, and toxicology services per facility protocol.
When should a nurse hold pyridoxine and contact the prescriber or pharmacist?
Hold for known sensitivity to pyridoxine or product ingredients, duplicate high-dose B6 from multiple sources without prescriber awareness, new progressive paresthesia or gait change suggesting toxicity or inadequate prophylaxis, levodopa monotherapy with a supplement exceeding 5 mg pyridoxine daily, or particulate/discolored parenteral solution.
References
-
U.S. National Library of Medicine. Pyridoxine Hydrochloride Injection, USP — prescribing information (Fresenius Kabi USA, LLC; ANDA 080618). DailyMed setid a56d11c0-b033-4201-85ff-fc710506481a.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a56d11c0-b033-4201-85ff-fc710506481a
-
National Institutes of Health Office of Dietary Supplements. Vitamin B6 — Health Professional Fact Sheet.https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/
-
U.S. National Library of Medicine. Pyridoxine Hydrochloride Injection, USP — label PDF. DailyMed.https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=a56d11c0-b033-4201-85ff-fc710506481a&type=pdf
-
MedlinePlus. Vitamin B6. U.S. National Library of Medicine.https://medlineplus.gov/ency/article/002402.htm
-
National Institutes of Health Office of Dietary Supplements. Vitamin B6 — Consumer Fact Sheet.https://ods.od.nih.gov/factsheets/VitaminB6-Consumer/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.